Abstract
Propofol (2,6-diisopropylphenol) is becoming the intravenous anesthetic of choice for ambulatory surgery in outpatients. It is extensively metabolized, with most of the administered dose appearing in the urine as glucuronide conjugates. Favorable operating conditions and rapid recovery are claimed as the main advantages in using propofol, whereas disadvantages include a relatively high incidence of apnea, and blood pressure reductions. Besides a literature summary of the pharmacodynamics, pharmacokinetics, toxicology, and clinical use, this review provides a deeper discussion on the current understanding of mechanism of action and structure-activity relationships, and recent findings on drug delivery technologies as applied to the improvement of propofol formulations. The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter g-aminobutyric acid (GABA) through GABA A receptors. Recent results from recombinant human GABA A receptor experiments and findings from the work exploring the effects at other receptors (e.g., glycine, nicotinic, and M1 muscarinic receptors) are reviewed. Studies showing its antiepileptic and anxiolytic properties are also discussed. The structure-activity relationships (SAR) of series of alkylphenols and p-X-substituted congeners have been reinvestigated. Interestingly, unlike the other congeners tested sofar, p-iodo-2,6- diisopropylphenol displayed anticonvulsant and anticonflict effects, but not sedative-hypnotic and anesthetic properties. Due to its high lipid-solubility, propofol was initially formulated as a solution with the surfactant Cremophor EL, but the occurrence of pain on injection and anaphylactoid reactions prompted to search for alternative formulations. Results from using cyclodextrins, water-soluble prodrugs, and adopting Bodor ’ s approach to the site-specific chemical delivery system (CDS), as well as the advantages provided by computer-controlled infusion systems, are examined in some detail.
Keywords: propofol, 2 diisoprovpylphenol, drug delivery, aminobutyric acid GABA, GABAa receptor, site specific chemical delivery system CDS, cloned GABA A Receptor, anticonvulsant, anxiolytic effects, alkylphenols, hypnotic activity, STERIMOL Descriptors, pharmacokinetic, drug monitoring, metabolism, toxicology, salmonella mutation, lipid formulations, saccharomices cerevisiae, prodrugs, chemical delivery systems CDS, target controlled infusion TCI, CLINICAL USE, Anesthesia, tomidate
Current Medicinal Chemistry
Title: Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery
Volume: 7 Issue: 2
Author(s): Giuseppe M. Trapani, Cosimo Altomare, Enrico Sanna, Giovanni Biggio and Gaetano Liso
Affiliation:
Keywords: propofol, 2 diisoprovpylphenol, drug delivery, aminobutyric acid GABA, GABAa receptor, site specific chemical delivery system CDS, cloned GABA A Receptor, anticonvulsant, anxiolytic effects, alkylphenols, hypnotic activity, STERIMOL Descriptors, pharmacokinetic, drug monitoring, metabolism, toxicology, salmonella mutation, lipid formulations, saccharomices cerevisiae, prodrugs, chemical delivery systems CDS, target controlled infusion TCI, CLINICAL USE, Anesthesia, tomidate
Abstract: Propofol (2,6-diisopropylphenol) is becoming the intravenous anesthetic of choice for ambulatory surgery in outpatients. It is extensively metabolized, with most of the administered dose appearing in the urine as glucuronide conjugates. Favorable operating conditions and rapid recovery are claimed as the main advantages in using propofol, whereas disadvantages include a relatively high incidence of apnea, and blood pressure reductions. Besides a literature summary of the pharmacodynamics, pharmacokinetics, toxicology, and clinical use, this review provides a deeper discussion on the current understanding of mechanism of action and structure-activity relationships, and recent findings on drug delivery technologies as applied to the improvement of propofol formulations. The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter g-aminobutyric acid (GABA) through GABA A receptors. Recent results from recombinant human GABA A receptor experiments and findings from the work exploring the effects at other receptors (e.g., glycine, nicotinic, and M1 muscarinic receptors) are reviewed. Studies showing its antiepileptic and anxiolytic properties are also discussed. The structure-activity relationships (SAR) of series of alkylphenols and p-X-substituted congeners have been reinvestigated. Interestingly, unlike the other congeners tested sofar, p-iodo-2,6- diisopropylphenol displayed anticonvulsant and anticonflict effects, but not sedative-hypnotic and anesthetic properties. Due to its high lipid-solubility, propofol was initially formulated as a solution with the surfactant Cremophor EL, but the occurrence of pain on injection and anaphylactoid reactions prompted to search for alternative formulations. Results from using cyclodextrins, water-soluble prodrugs, and adopting Bodor ’ s approach to the site-specific chemical delivery system (CDS), as well as the advantages provided by computer-controlled infusion systems, are examined in some detail.
Export Options
About this article
Cite this article as:
Trapani M. Giuseppe, Altomare Cosimo, Sanna Enrico, Biggio Giovanni and Liso Gaetano, Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery, Current Medicinal Chemistry 2000; 7 (2) . https://dx.doi.org/10.2174/0929867003375335
DOI https://dx.doi.org/10.2174/0929867003375335 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Kernel-Based Feature Selection Techniques for Transport Proteins Based on Star Graph Topological Indices
Current Topics in Medicinal Chemistry Metabolism of Drugs Used in the Therapy of Seizures: An Analytical Point of View. Part 1
Current Drug Metabolism Tissue Distribution and Pharmacodynamics of Rivastigmine after Intranasal and Intravenous Administration in Rats
Current Alzheimer Research The Role of Extracellular Adenosine in Chemical Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical Aspects
Current Topics in Medicinal Chemistry An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) A Review on the Arylpiperazine Derivatives as Potential Therapeutics for the Treatment of Various Neurological Disorders
Current Drug Targets Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews <i>Cannabis Sativa</i> L. Flower and Bud Extracts Inhibited <i>In vitro</i> Cholinesterases and β-Secretase Enzymes Activities: Possible Mechanisms of Cannabis Use in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets fMRI Simulator Training to Suppress Head Motion
Neuroscience and Biomedical Engineering (Discontinued) Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Controlled Somatic and Germline Copy Number Variation in the Mouse Model
Current Genomics University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology
Current Alzheimer Research Pharmacology and Therapeutic Applications of A3 Receptor Subtype
Current Topics in Medicinal Chemistry Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Development of Polymeric Nanocarriers for Brain Targeted Delivery of Atorvastatin: A Quality-By-Design Approach
Drug Delivery Letters Early Prediction of Preeclampsia: Hope for Early Intervention?
Current Women`s Health Reviews Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders
Current Neuropharmacology New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design